Skip to main content
TipRanks
Go Ultimate75% OFF
Ollin Biosciences logo

Ollin Biosciences: Valuation, Funding & Investors

Ollin Biosciences is a clinical-stage biotechnology company focused on developing innovative therapeutics for retinal diseases. The company is advancing OLN324, a VEGF/Ang2 bispecific antibody candidate, into global Phase 3 trials for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD).

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$330M
Total Funding Rounds
1
Latest Funding Amount
$330M
Latest Funding Round
Series B

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jun 25, 2026Series B$330.00M―

Investors

Investor NameFunding Round
TCGXSeries B
ARCH Venture PartnersSeries B

Similar Companies

A snapshot of private companies similar to Ollin Biosciences, helping you discover and navigate related company profiles.

Related News and Analysis